학술논문
Infusional gemcitabine plus docetaxel/melphalan/carboplatin (GemDMC) +/- bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755